Rossella Medori

3.5k total citations
36 papers, 2.6k citations indexed

About

Rossella Medori is a scholar working on Psychiatry and Mental health, Neurology and Clinical Psychology. According to data from OpenAlex, Rossella Medori has authored 36 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 12 papers in Neurology and 9 papers in Clinical Psychology. Recurrent topics in Rossella Medori's work include Schizophrenia research and treatment (13 papers), Parkinson's Disease Mechanisms and Treatments (10 papers) and Obsessive-Compulsive Spectrum Disorders (6 papers). Rossella Medori is often cited by papers focused on Schizophrenia research and treatment (13 papers), Parkinson's Disease Mechanisms and Treatments (10 papers) and Obsessive-Compulsive Spectrum Disorders (6 papers). Rossella Medori collaborates with scholars based in Belgium, United States and Italy. Rossella Medori's co-authors include Robin Emsley, Jonathan Rabinowitz, Pierluigi Gambetti, Olivier Rascol, E Lugaresi, Agostino Baruzzi, Pietro Cortelli, Paolo Tinuper, Pasquale Montagna and Delphine Charvin and has published in prestigious journals such as New England Journal of Medicine, American Journal of Psychiatry and Neurology.

In The Last Decade

Rossella Medori

36 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rossella Medori Belgium 26 984 797 596 505 405 36 2.6k
Rudie Kortekaas Netherlands 22 694 0.7× 253 0.3× 376 0.6× 402 0.8× 333 0.8× 50 2.5k
Mei Hong Xiu China 34 1000 1.0× 506 0.6× 151 0.3× 271 0.5× 683 1.7× 77 2.8k
Da Chun Chen China 32 964 1.0× 422 0.5× 181 0.3× 246 0.5× 717 1.8× 73 2.7k
T. G. Bolwig Denmark 32 1.5k 1.5× 432 0.5× 516 0.9× 312 0.6× 955 2.4× 77 3.6k
Simon Červenka Sweden 26 619 0.6× 300 0.4× 345 0.6× 383 0.8× 445 1.1× 81 2.4k
Jun‐ichi Iga Japan 28 630 0.6× 698 0.9× 135 0.2× 203 0.4× 430 1.1× 105 2.2k
Carl M. Sellgren Sweden 34 1.4k 1.4× 594 0.7× 201 0.3× 603 1.2× 314 0.8× 81 3.4k
Michael Sanfilipo United States 24 893 0.9× 273 0.3× 221 0.4× 139 0.3× 476 1.2× 40 2.4k
Hisanobu Kaiya Japan 25 410 0.4× 356 0.4× 168 0.3× 132 0.3× 393 1.0× 120 1.9k
Ignácio F. Mata United States 40 1.7k 1.8× 1.2k 1.5× 2.9k 4.9× 1.0k 2.0× 1.3k 3.2× 166 5.9k

Countries citing papers authored by Rossella Medori

Since Specialization
Citations

This map shows the geographic impact of Rossella Medori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rossella Medori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rossella Medori more than expected).

Fields of papers citing papers by Rossella Medori

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rossella Medori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rossella Medori. The network helps show where Rossella Medori may publish in the future.

Co-authorship network of co-authors of Rossella Medori

This figure shows the co-authorship network connecting the top 25 collaborators of Rossella Medori. A scholar is included among the top collaborators of Rossella Medori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rossella Medori. Rossella Medori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rascol, Olivier, et al.. (2022). A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Movement Disorders. 37(5). 1088–1093. 29 indexed citations
2.
Seppi, Klaus, Rossella Medori, Petra Lührs, et al.. (2021). Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study. Journal of Parkinson s Disease. 11(3). 1079–1089. 44 indexed citations
3.
Zeitlinger, Markus, Martin Bauer, Roman Reindl‐Schwaighofer, et al.. (2021). A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. European Journal of Clinical Pharmacology. 77(10). 1473–1484. 43 indexed citations
4.
Volc, Dieter, Werner Poewe, Alexandra Kutzelnigg, et al.. (2020). Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. The Lancet Neurology. 19(7). 591–600. 105 indexed citations
5.
Charvin, Delphine, Rossella Medori, Robert A. Hauser, & Olivier Rascol. (2018). Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature Reviews Drug Discovery. 17(11). 804–822. 209 indexed citations
6.
Buitelaar, Jan K. & Rossella Medori. (2009). Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. European Child & Adolescent Psychiatry. 19(4). 325–340. 68 indexed citations
7.
Emsley, Robin, Rossella Medori, Liezl Koen, et al.. (2008). Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. Journal of Clinical Psychopharmacology. 28(2). 210–213. 78 indexed citations
8.
Medori, Rossella, Josep Antoni Ramos‐Quiroga, Miguel Casas, et al.. (2008). A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry. 63(10). 981–989. 144 indexed citations
9.
Mauri, Massimo Carlo, Martin R. Turner, L.S. Volonteri, Rossella Medori, & Wolfgang Maier. (2008). Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. International Journal of Psychiatry in Clinical Practice. 13(1). 36–47. 4 indexed citations
10.
Bräunig, Peter, Emilio Sacchetti, & Rossella Medori. (2008). Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study. International Journal of Psychiatry in Clinical Practice. 12(1). 74–77. 8 indexed citations
11.
Kissling, Werner, et al.. (2007). Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients. Human Psychopharmacology Clinical and Experimental. 22(8). 505–513. 22 indexed citations
12.
Schmauß, Max, et al.. (2007). Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. International Clinical Psychopharmacology. 22(2). 85–92. 27 indexed citations
13.
Currier, Glenn W. & Rossella Medori. (2006). Orally Versus Intramuscularly Administered Antipsychotic Drugs in Psychiatric Emergencies. Journal of Psychiatric Practice. 12(1). 30–40. 33 indexed citations
14.
Emsley, Robin, Jonathan Rabinowitz, & Rossella Medori. (2006). Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia. American Journal of Psychiatry. 163(4). 743–745. 97 indexed citations
15.
Medori, Rossella, Erik Mannaert, & Gerhard Gründer. (2005). Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. European Neuropsychopharmacology. 16(4). 233–240. 29 indexed citations
16.
Llorca, Pierre‐Michel, et al.. (2005). Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology. 20(3). 121–130. 107 indexed citations
17.
Chrzanowski, W., et al.. (2004). Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. International Clinical Psychopharmacology. 19(5). 259–269. 14 indexed citations
18.
Medori, Rossella, Valeria Manetto, H. Y. Chen, et al.. (1992). Fatal Familial Insomnia, a Prion Disease with a Mutation at Codon 178 of the Prion Protein Gene. New England Journal of Medicine. 326(7). 444–449. 414 indexed citations
19.
Medori, Rossella, David S. Younger, Hai Won Chang, et al.. (1991). Becker muscular dystrophy or spinal muscular atrophy?—Dystrophin studies resolve conflicting results of electromyography and muscle biopsy. Neuromuscular Disorders. 1(3). 195–200. 9 indexed citations
20.
Medori, Rossella, Michael H. Brooke, & R Waterston. (1989). Two dissimilar brothers with Becker's dystrophy have an identical genetic defect. Neurology. 39(11). 1493–1493. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rudie Kortekaas Breakdown of academic impact, for papers by Mei Hong Xiu Breakdown of academic impact, for papers by Da Chun Chen Breakdown of academic impact, for papers by T. G. Bolwig Breakdown of academic impact, for papers by Simon Červenka Breakdown of academic impact, for papers by Jun‐ichi Iga Breakdown of academic impact, for papers by Carl M. Sellgren Breakdown of academic impact, for papers by Michael Sanfilipo Breakdown of academic impact, for papers by Hisanobu Kaiya Breakdown of academic impact, for papers by Ignácio F. Mata
Rankless by CCL
2026